Tabur, S. Et Al. 2016. Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome. ENDOCRINE , vol.53, no.2 , 465-470.

Tabur, S., Oztuzcu, S., Oguz, E., Demiryurek, S., Dagli, H., Alasehirli, B., ... Ozkaya, M.(2016). Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome. ENDOCRINE , vol.53, no.2, 465-470.

Tabur, Suzan Et Al. "Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome," ENDOCRINE , vol.53, no.2, 465-470, 2016

Tabur, Suzan Et Al. "Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome." ENDOCRINE , vol.53, no.2, pp.465-470, 2016

Tabur, S. Et Al. (2016) . "Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome." ENDOCRINE , vol.53, no.2, pp.465-470.

@article{article, author={Suzan Tabur Et Al. }, title={Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome}, journal={ENDOCRINE}, year=2016, pages={465-470} }